Skip to main content
SpringerLink
Log in

Anti-angiogenic Therapies in Colorectal Cancer

  • Chapter
  • First Online:
Molecular Mechanisms of Angiogenesis

  • 1272 Accesses

Abstract

Anti-angiogenic therapies (AAT) such bevacizumab (monoclonal antibody directed against VEGF) and more recently aflibercept (VEGF-Trap) and regorafenib (oral multikinase inhibitor) have been approved in several indications in metastatic colorectal cancer, and we will discuss them further.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AAT:

Anti-angiogenic therapies

CEA:

Carcinoembryonic antigen

Ang:

Angiopoietin

BEVA:

Bevacizumab

CRS:

Cytoreductive surgery

CRLM:

Colorectal liver metastasis

FOLFIRI:

Folinic acid-fluorouracil-irinotecan

FOLFOX:

Folinic acid-fluorouracil-oxaliplatin

HIPEC:

Hyperthermic intraperitoneal chemotherapy

OS:

Overall survival

PC:

Peritoneal carcinomatosis

PDGFR:

Platelet-derived growth factor receptor

PFS:

Progression-free survival

PlGF:

Placental growth factor

VEGF:

Vascular endothelial growth factor

VEGFR:

Vascular endothelial growth factor receptor

Bibliography

  • Adam R, Delvart V, Pascal G et al (2004a) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240(4): 644–647

    PubMed Central  PubMed  Google Scholar 

  • Adam R, Pascal G, Castaing D et al (2004b) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240(6):1052–1061; discussion 61–64

    Article  PubMed Central  PubMed  Google Scholar 

  • Allegra CJ, Yothers G, O’Connell MJ et al (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29(1):11–16

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Allegra CJ, Lakomy R, Tabernero J et al (2012) Effects of prior bevacizumab use on outcomes from the VELOUR study: a phase III study of aflibercept and FOLFIRI in patients with metastatic colorectal cancer after failure of an oxaliplatin regimen. J Clin Oncol 30(Suppl):3505

    Google Scholar 

  • Allegra CJ, Yothers G, O’Connell MJ et al (2013) Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 31(3):359–364

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Almog N (2010) Molecular mechanisms underlying tumor dormancy. Cancer Lett 294(2):139–146

    Article  CAS  PubMed  Google Scholar 

  • Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N England J Med 350(23):2343–2351

    Article  CAS  Google Scholar 

  • Andreou A, Aloia TA, Brouquet A et al (2013) Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 257(6):1079–1088

    Article  PubMed  Google Scholar 

  • Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J (2009) Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16(6):1553–1559

    Article  PubMed  Google Scholar 

  • Azoulay D, Castaing D, Krissat J et al (2000) Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 232(5):665–672

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 8(8):592–603.

    Google Scholar 

  • Blazer DG 3rd, Kishi Y, Maru DM et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26(33): 5344–5351

    Article  PubMed  Google Scholar 

  • Cao C, Yan TD, Black D, Morris DL (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16:2152–2165

    Article  PubMed  Google Scholar 

  • Chua TC, Morris DL, Saxena A et al (2011) Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol 18(6):1560–1567

    Article  PubMed  Google Scholar 

  • Chun YS, Vauthey JN, Ribero D et al (2007) Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg 11(11):1498–1504; discussion 504–505

    Article  PubMed  Google Scholar 

  • de Gramont A, Van Cutsem E, Schmoll HJ et al (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13(12):1225–1233

    Article  PubMed  Google Scholar 

  • De Vita F, Orditura M, Lieto E et al (2004) Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100(2):270–278

    Article  PubMed  Google Scholar 

  • Des Guetz G, Uzzan B, Nicolas P et al (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94(12): 1823–1832

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ding BS, Nolan DJ, Butler JM et al (2010) Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 468(7321):310–315

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Drixler TA, Vogten MJ, Ritchie ED et al (2002) Liver regeneration is an angiogenesis- associated phenomenon. Ann Surg 236(6):703–711; discussion 11–12

    Article  PubMed Central  PubMed  Google Scholar 

  • Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239

    Article  CAS  PubMed  Google Scholar 

  • Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681–685

    Article  PubMed  Google Scholar 

  • Eveno C, le Maignan C, Soyer P, Camus M, Barranger E, Pocard M (2011a) Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication. Clin Res Hepatol Gastroenterol 35(2):135–139

    Article  CAS  PubMed  Google Scholar 

  • Eveno C, Soyer P, Teixeira L, Staudacher L, Pocard M (2011b) Anastomotic dehiscence during treatment with bevacizumab 5 years after colo-anal anastomosis with proposition for management without stopping chemotherapy. Clin Res Hepatol Gastroenterol 35(8–9):594–596

    Article  CAS  PubMed  Google Scholar 

  • Eveno C, Passot G, Goéré D et al (2013) Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol [Epub ahead of print]

    Google Scholar 

  • Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1):38–47

    Article  CAS  PubMed  Google Scholar 

  • Franko J, Shi Q, Goldman CD et al (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30:263–267

    Article  PubMed Central  PubMed  Google Scholar 

  • Gallagher DJ, Kemeny N (2010) Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78(3–4):237–248

    Article  PubMed  Google Scholar 

  • Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12): 1539–1544

    Article  CAS  PubMed  Google Scholar 

  • Glehen O, Mohamed F, Gilly FN (2004) Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5:219–228

    Article  PubMed  Google Scholar 

  • Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326–5334

    Article  CAS  PubMed  Google Scholar 

  • Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312

    Article  CAS  PubMed  Google Scholar 

  • Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26(11):1830–1835

    Article  CAS  PubMed  Google Scholar 

  • Hochster HS, Hart LL, Ramanathan RK et al (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26(21):3523–3529

    Article  CAS  PubMed  Google Scholar 

  • Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393–11398

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1(2):149–153

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342

    Article  CAS  PubMed  Google Scholar 

  • Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P (2004) A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 240(6): 1037–1049; discussion 49–51

    Article  PubMed Central  PubMed  Google Scholar 

  • Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271(1):58–65

    Article  CAS  PubMed  Google Scholar 

  • Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23(16):3706–3712

    Article  CAS  PubMed  Google Scholar 

  • Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Karayiannakis AJ, Syrigos KN, Zbar A et al (2002) Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 131(5):548–555

    Article  PubMed  Google Scholar 

  • Karoui M, Vigano L, Goyer P et al (2010) Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases. Br J Surg 97(9):1354–1362

    Article  CAS  PubMed  Google Scholar 

  • Karoui M, Roudot-Thoraval F, Mesli F et al (2011) Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum 54(8):930–938

    Article  PubMed  Google Scholar 

  • Kishi Y, Zorzi D, Contreras CM et al (2010) Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17(11):2870–2876

    Article  PubMed  Google Scholar 

  • Klinger M, Tamandl D, Eipeldauer S et al (2010) Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 17(8): 2059–2065

    Article  PubMed  Google Scholar 

  • Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22):3677–3683

    Article  PubMed Central  PubMed  Google Scholar 

  • Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25(16):2198–2204

    Article  CAS  PubMed  Google Scholar 

  • Lim C, Cauchy F, Azoulay D, Farges O, Ronot M, Pocard M (2013) Tumour progression and liver regeneration–insights from animal models. Nat Rev Gastroenterol Hepatol 10(8):452–462

    Article  CAS  PubMed  Google Scholar 

  • Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116(10):2610–2621

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259

    Article  PubMed Central  PubMed  Google Scholar 

  • Miles D, Harbeck N, Escudier B et al (2011) Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 29(1):83–88

    Article  CAS  PubMed  Google Scholar 

  • Nadalin S, Testa G, Malago M et al (2004) Volumetric and functional recovery of the liver after right hepatectomy for living donation. Liver Transpl 10(8):1024–1029

    Article  PubMed  Google Scholar 

  • Naumov GN, Akslen LA, Folkman J (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell cycle 5(16):1779–1787

    Article  CAS  PubMed  Google Scholar 

  • Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3): 220–231

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Passot G, Bakrin N, Garnier L et al (2014) Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment? Eur J Cancer 50(4):722–730

    Google Scholar 

  • Passot G, Dupré A, Rivoire M, Mohamed F, Bakrin N, Glehen O (2012) Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model. Clin Transl Oncol 14(12):931–936

    Article  CAS  PubMed  Google Scholar 

  • Pericay C, Folprecht G (2012) Phase 2 randomized, noncomparative open-label study of aflibercept and Modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM). Ann Oncol 23(Suppl 4):O-0024

    Google Scholar 

  • Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110(12):2761–2767

    Article  PubMed  Google Scholar 

  • Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18(2):299–304

    Article  CAS  PubMed  Google Scholar 

  • Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G, Stahl N, Yancopoulos GD (2007) VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 104:18363–18370

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013–2019

    Article  CAS  PubMed  Google Scholar 

  • Shimizu H, Miyazaki M, Wakabayashi Y et al (2001) Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol 34(5):683–689

    Article  CAS  PubMed  Google Scholar 

  • Sorbye H, Mauer M, Gruenberger T et al (2012) Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 255(3):534–539

    Article  PubMed  Google Scholar 

  • Starlinger P, Alidzanovic L, Schauer D et al (2012) Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. Br J Cancer 107(6): 961–966

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Stillwell AP, Buettner PG, Ho YH (2010) Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 34(4):797–807

    Article  CAS  PubMed  Google Scholar 

  • Tamandl D, Klinger M, Eipeldauer S et al (2011) Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18(2):421–430

    Article  PubMed  Google Scholar 

  • Taniguchi E, Sakisaka S, Matsuo K, Tanikawa K, Sata M (2001) Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 49(1):121–130

    Article  CAS  PubMed  Google Scholar 

  • Van Buren G 2nd, Yang AD, Dallas NA et al (2008) Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 26(11):1836–1842

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842–1847

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499–3506

    Article  PubMed  Google Scholar 

  • van der Wal GE, Gouw AS, Kamps JA et al (2012) Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg 255(1):86–94

    Article  PubMed  Google Scholar 

  • Venderbosch S, de Wilt JH, Teerenstra S et al (2011) Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 18(12):3252–3260

    Article  PubMed Central  PubMed  Google Scholar 

  • Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743

    Article  PubMed  Google Scholar 

  • Welch S, Spithoff K, Rumble RB, Maroun J (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21(6): 1152–1162

    Article  CAS  PubMed  Google Scholar 

  • Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255

    Article  CAS  PubMed  Google Scholar 

  • Wong RSC, Barbachano Y, Chau I, Valle J, Hickish T et al (2009) BOXER: a multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. Eur J Cancer Suppl 7(2):344–345

    Article  Google Scholar 

  • Wong R, Cunningham D, Barbachano Y et al (2011) A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22:2042–2048

    Article  CAS  PubMed  Google Scholar 

  • Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN (2008) Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 15(10):2765–2772

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Oncologic and Digestive Unit, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, 2 rue Amboise Paré, 75475, Paris Cedex 10, France

    Clarisse Eveno MD, PhD & Marc Pocard MD, PhD

  2. Université Paris-Diderot, Sorbonne Paris Cité, 10 rue de Verdun, 75010, Paris, France

    Clarisse Eveno MD, PhD & Marc Pocard MD, PhD

  3. INSERM U965, 2 rue Amboise Paré, 75475, Paris Cedex 10, France

    Clarisse Eveno MD, PhD & Marc Pocard MD, PhD

Authors
  1. Clarisse Eveno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Pocard MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Pocard MD, PhD .

Editor information

Editors and Affiliations

  1. UMR 1036, Biologie du Cancer et de l’Infection, Institut de Recherches en Technologies et Sciences pour le Vivant, Université Grenoble-Alpes, Grenoble, France

    Jean-Jacques Feige

  2. Institute for Research on Cancer and aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France

    Gilles Pagès

  3. CNRS UMR8161, Institut Pasteur de Lille, Institut de Biologie de Lille, Lille, France

    Fabrice Soncin

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag France

About this chapter

Cite this chapter

Eveno, C., Pocard, M. (2014). Anti-angiogenic Therapies in Colorectal Cancer. In: Feige, JJ., Pagès, G., Soncin, F. (eds) Molecular Mechanisms of Angiogenesis. Springer, Paris. https://doi.org/10.1007/978-2-8178-0466-8_19

Download citation

Publish with us

Policies and ethics

Search

Navigation